LABORATORIO FARMAC.ERFO (RK7) — Cash Flow-to-Debt Ratio
LABORATORIO FARMAC.ERFO (RK7) has a Cash Flow-to-Debt Ratio of 0.57x as of December 2023, meaning its operating cash flow of €1.30 Million could theoretically repay 1% of its total liabilities (€2.26 Million) in one year. See LABORATORIO FARMAC.ERFO free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
LABORATORIO FARMAC.ERFO Cash Flow-to-Debt Ratio (2021–2023)
Historical debt coverage capacity for LABORATORIO FARMAC.ERFO across 3 annual periods. Also explore RK7 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for LABORATORIO FARMAC.ERFO (2021–2023)
Year-by-year debt coverage analysis for LABORATORIO FARMAC.ERFO. For market capitalisation and broader financial context, see market value of LABORATORIO FARMAC.ERFO.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | 0.57x | €1.30 Million | €2.26 Million | ▲ +691.9% |
| 2022 | 0.07x | €761.80K | €10.53 Million | ▼ -93.0% |
| 2021 | 1.03x | €2.27 Million | €2.21 Million | — |